Inhibition of miR-140-3p or miR-155-5p by antagomir treatment sensitize chordoma cells to chemotherapy drug treatment by increasing PTEN expression.

08:00 EDT 10th April 2019 | BioPortfolio

Summary of "Inhibition of miR-140-3p or miR-155-5p by antagomir treatment sensitize chordoma cells to chemotherapy drug treatment by increasing PTEN expression."

Previous researches suggested microRNA-140-3p (miR-140-3p) and miR-155-5p as cancer promotor in chordoma. We aimed to investigate the mechanisms of these two miRNAs in chordoma cells. Patient-derived chordoma cell lines were established in vitro. Expressions of miR-140-3p or miR-155-5p were measured by quantitative real-time polymerase chain reaction and their functions were inhibited by antagomir treatment. Malignancy of chordoma cells was assessed by cell viability, proliferation, apoptosis, colony formation and transwell invasion assays as well as western blot evaluating epithelial-to-mesenchymal transition. Sensitivity of chordoma cells was assessed by cell viability and apoptosis assays. Protein level of phosphatase and tensin homolog (PTEN) and phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathway were assessed by western blot. Interaction of miR-140-3p and miR-155-5p with the 3' untranslated region of PTEN mRNA was verified by luciferase reporter assay. BpV was used to inhibit PTEN activity. The expressions of miR-140-3p and miR-155-5p were enhanced in chordoma cells and inhibited by treatment of antagomirs. Inhibition of miR-140-3p or miR-155-5p significantly reduced the malignancy of patient-derived chordoma cells and activation of PI3K-Akt-mTOR signaling, while significantly increasing the sensitivity to doxorubicin, paclitaxel or cisplatin treatment and PTEN protein level. PTEN was verified as a direct target of miR-140-3p and miR-155-5p and its inhibition by bpV treatment largely abrogated the chemotherapy sensitizing effect of anti-miR-140-3p or anti-miR-155-5p on chordoma cells. Collectively, inhibition of miR-140-3p or miR-155-5p significantly reduced the malignancy of chordoma cells and increased their sensitivity to chemotherapy by releasing PTEN expression.


Journal Details

This article was published in the following journal.

Name: European journal of pharmacology
ISSN: 1879-0712


DeepDyve research library

PubMed Articles [40444 Associated PubMed Articles listed on BioPortfolio]

Inhibition of microRNA-155 attenuates concanavalin A-induced autoimmune hepatitis by regulating Treg/Th17 cell differentiation.

Autoimmune hepatitis (AIH) is a chronic progressive autoimmune disease characterized by hepatic inflammation. This study aimed to investigate the effect of antagomir-155 on Concanavalin A (ConA)-induc...

MicroRNA-137 inhibits autophagy and chemosensitizes pancreatic cancer cells by targeting ATG5.

Autophagy play an important role in tumor chemotherapy resistance. It has been reported that miR-137 expression was reducedand involved in the regulation of sensitivity of PC cells to chemotherapy. Ho...

Oestrogen-related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1.

Chemotherapy resistance is one of the major challenges for the treatment of osteosarcoma (OS). The potential roles of oestrogenic signals in the chemoresistance of OS cells were investigated. As compa...

Chemoradiotherapy for Unresectable INI1-negative Chordoma in a Child.

The characteristics of chordomas in children are distinct from those in adults. In particular, the prognosis of patients with INI1-negative chordoma is dismal. The standard treatment for localized cho...

AntagomiR-103 and -107 Treatment Affects Cardiac Function and Metabolism.

MicroRNA-103/107 regulate systemic glucose metabolism and insulin sensitivity. For this reason, inhibitory strategies for these microRNAs are currently being tested in clinical trials. Given the high ...

Clinical Trials [11822 Associated Clinical Trials listed on BioPortfolio]

CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma

In chordoma cell lines and patient biopsies, the p16 (CDKN2A) tumor suppressor is consistently deleted. Thus, chordomas are an example of a tumor with universal activation of the cyclin-de...

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

QUILT 3.091 Chordoma Vaccine: Phase 1B/2 NANT Chordoma Vaccine vs Radiation in Subjects with Unresectable Chordoma.

Identifying New Families With Multiple Members Affected by Chordoma

RATIONALE: Identifying new families with members affected by chordoma may help the study of chordoma in the future. PURPOSE: This clinical trial is identifying new families with multiple ...

Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma

This phase I trial studies the side effects of nivolumab with or without stereotactic radiosurgery in treating patients with chordoma that has come back or spread from where it started to ...

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

This phase II trial studies how well nivolumab and relatlimab work in treating participants with chordoma that has spread to other places in the body. Monoclonal antibodies, such as nivolu...

Medical and Biotech [MESH] Definitions

Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.

Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.

Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.

Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)

Quick Search


DeepDyve research library

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

MicroRNAs (miRNAs)
A microRNA (abbreviated miRNA) is a small non-coding RNA molecule (containing about 22 nucleotides) found in plants, animals, and some viruses.  Key findings: miRNA is involved in the normal functioning of eukaryotic cells, so has dysregulation...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Searches Linking to this Article